Responses were deep and durable, with 65% ongoing at clinical cutoff Results support continued evaluation of the ...
One night over tacos, my friends shared an impromptu social media presentation... starring Jacque’s husband, Kevin. “Look! He ...
Updated Phase 1b dataset provides nearly 18 months of median follow-up and shows the durability of clinical benefit observed with givastomigClinical activity observed across CLDN18.2 expression levels ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results